Kyowa Hakko President Sets Goals To Overtake Genentech
This article was originally published in PharmAsia News
Executive Summary
At a Tokyo press briefing, Kyowa Hakko President Yuzuru Matsuda disclosed that he and John Maraganore, CEO of American company Alnylam Pharmaceuticals, had made a bet to see which company would first overtake Genentech. Matsuda also stated that Kyowa will be able to achieve similar growth enjoyed by Genentech and Amgen if it utilizes its advantage in antibody technology. Commenting on RNAi drug development, in which Kyowa and Alnylam formed an exclusive alliance to develop and commercialize the RNAi therapeutic drug ALN-RSV01, Matsuda said Kyowa has to keep a venture enterprise spirit and develop two fronts in both antibody and RNAi. (Click here for more - Japanese language
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.